MedTrace Logo

Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS

NCT07138274 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-08-22

No results posted yet for this study

Summary

single-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of overnight metyrapone in patients with MACS.

Conditions

  • Mild Autonomous Cortisol Secretion (MACS)
  • Autonomous Cortisol Secretion (ACS)

Interventions

DRUG

Metyrapone 250 mg Oral Tablets

Subjects will receive metyrapone beginning at 500 mg and titrating up to 1000 mg

DRUG

Placebo

Subjects will receive placebo at 500 mg dose and titrated up to 1000 mg to match interventional arm and prevent unblinding

Sponsors & Collaborators

Principal Investigators

  • Irina Bancos, MD, MS · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2031-06-30
Completion
2031-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07138274 on ClinicalTrials.gov